Literature DB >> 10479392

Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination.

G Hermans1, U Denzer, A Lohse, J Raus, P Stinissen.   

Abstract

Myelin basic protein (MBP)-reactive T cells may play an important role in the autoimmune pathogenesis of multiple sclerosis (MS). MBP-reactive T cells can be specifically targeted by T cell vaccination, a procedure whereby MS patients are immunized with attenuated autologous MBP reactive T cells. T cell vaccination induces immune responses to the vaccine cells together with a depletion of MBP reactive T cells. Forty-nine MS patients were treated with T cell vaccination in an extended phase I trial to study the safety, immune responses and clinical effects of T cell vaccination. In the present paper the immune responses towards the vaccine cells were characterized. Substantial long-term in vitro proliferative responses were observed in all treated patients. Some patients, immunized with different clones, displayed distinct proliferative reactivity against the various vaccine clones, suggesting unequal immunogenic properties of these clones. Reactive TCRalphabeta(+), CD8(+)and CD4(+)T cells, and to a lesser extent, gammadelta T cells and NK cells were observed to in vitro stimulation with the vaccine cells. A small fraction only of CD8(+)T cells expressed cytolytic and inhibitory anti-clonotypic reactivity against the vaccine cells. Stimulation with the vaccine clones predominantly induced expression of pro-inflammatory cytokines in these mixed cultures, although one vaccine clone consistently induced production of IL-4. CD4(+)T cells are the major cytokine-producing cells in these anti-vaccine lines. We could not detect upregulated antibody responses to the vaccine cells in most patients, although a temporary antibody response was observed in one patient. In conclusion, immunization with attenuated autoreactive T cells induces a complex cellular response specifically targeted at the vaccine cells, but no antibody responses. These data provide further insights into the mechanisms of T cell vaccination and improve our understanding of the complex regulatory networks of autoreactive T cells. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479392     DOI: 10.1006/jaut.1999.0314

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  11 in total

Review 1.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

Review 2.  Multiple sclerosis in childhood and adolescence: clinical features and management.

Authors:  O Pinhas-Hamiel; I Sarova-Pinhas; A Achiron
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  Anti-T-cell humoral and cellular responses in healthy BALB/c mice following immunization with ovalbumin or ovalbumin-specific T cells.

Authors:  Xiao-Yu Zhang; Xiang-Guo Liu; Wei Wang; Wen-Chao Wang; Xiao-Ming Gao
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

Review 4.  Insights into the immunopathogenesis of multiple sclerosis.

Authors:  Niels Hellings; Jef Raus; Piet Stinissen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 5.  The mechanisms and applications of T cell vaccination for autoimmune diseases: a comprehensive review.

Authors:  Xin Huang; Haijing Wu; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

6.  Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis.

Authors:  Florence Jambou; Wei Zhang; Monique Menestrier; Isabelle Klingel-Schmitt; Olivier Michel; Sophie Caillat-Zucman; Abderrahim Aissaoui; Ludovic Landemarre; Sonia Berrih-Aknin; Sylvia Cohen-Kaminsky
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 7.  Vaccines for multiple sclerosis: progress to date.

Authors:  Jorge Correale; Mauricio Farez; Wendy Gilmore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  Autologous T-cell vaccination for multiple sclerosis: a perspective on progress.

Authors:  Arthur A Vandenbark; Rivka Abulafia-Lapid
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

9.  T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study.

Authors:  A Van der Aa; N Hellings; R Medaer; G Gelin; Y Palmers; J Raus; P Stinissen
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

10.  T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.

Authors:  Dimitrios Karussis; Hagai Shor; Julia Yachnin; Naama Lanxner; Merav Amiel; Keren Baruch; Yael Keren-Zur; Ofra Haviv; Massimo Filippi; Panayiota Petrou; Shalom Hajag; Urania Vourka-Karussis; Adi Vaknin-Dembinsky; Salim Khoury; Oded Abramsky; Henri Atlan; Irun R Cohen; Rivka Abulafia-Lapid
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.